-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Sunflower Pharmaceutical's announcement, the company used 400 million yuan of idle capital to purchase fixed income floating income wealth management products, involving China Merchants Bank, Industrial Bank, Shanghai Pudong Development Bank, and China CITIC Bank related products. Among them, SPDB Wealth Management Zhou Zhou of the Harbin Branch Sales Department of Shanghai Pudong Development Bank held 100 million yuan for a minimum period of 100 million yuan. The performance comparison benchmark was 2.0%. The starting date was September 18, 2026. As of the announcement date, the unexpired amount of the company's cash management was 1,580 billion yuan.
Share
Listen to the news
According to Sunflower Pharmaceutical's announcement, the company used 400 million yuan of idle capital to purchase fixed income floating income wealth management products, involving China Merchants Bank, Industrial Bank, Shanghai Pudong Development Bank, and China CITIC Bank related products. Among them, SPDB Wealth Management Zhou Zhou of the Harbin Branch Sales Department of Shanghai Pudong Development Bank held 100 million yuan for a minimum period of 100 million yuan. The performance comparison benchmark was 2.0%. The starting date was September 18, 2026. As of the announcement date, the unexpired amount of the company's cash management was 1,580 billion yuan.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending